Form 4: Inovio Pharmaceuticals CEO Reports Stock Transactions
SEC Form 4 Filing
CEO Jacqueline Elizabeth Shea reports acquisition and disposal of Inovio Pharmaceuticals stock related to restricted stock units.
Summary
- Jacqueline Elizabeth Shea, CEO of Inovio Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On May 10, 2024, 5,500 shares of common stock were acquired upon vesting of restricted stock units.
- Also on May 10, 2024, 2,392 shares were disposed of to cover tax withholding obligations at a price of $10.65 per share.
- Following these transactions, Shea directly owns 23,620 shares of Inovio Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| May 10, 2023 | 5,500 restricted stock units vested. |
| January 24, 2024 | 1-for-12 reverse stock split effected by the Issuer. |
| May 10, 2024 | 5,500 restricted stock units vested and 2,392 shares disposed of for tax obligations. |
| May 10, 2025 | 5,500 restricted stock units will vest. |
| May 13, 2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.